{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8(5)"],"submitter":["Zelniker TA"],"pubmed_abstract":["<h4>Importance</h4>Dapagliflozin reduces the risk of hospitalizations for heart failure and the progression of chronic kidney disease in patients with and without type 2 diabetes (T2D), whereas the effects on reducing atherosclerotic events appear less clear.<h4>Objective</h4>To explore whether N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin T (hsTnT) levels can identify a subset of patients with T2D at higher risk and who might benefit more from dapagliflozin with regard to atherosclerotic events.<h4>Design, setting, and participants</h4>This was a secondary analysis of the DECLARE-TIMI 58 trial, a randomized clinical trial of dapagliflozin in patients with T2D and either multiple risk factors for atherosclerotic cardiovascular disease (ASCVD; a"],"journal":["JAMA cardiology"],"pagination":["503-509"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9979005"],"repository":["biostudies-literature"],"pubmed_title":["Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes: A Secondary Analysis of the DECLARE-TIMI 58 Trial."],"pmcid":["PMC9979005"],"pubmed_authors":["Jarolim P","Raz I","Wiviott SD","Langkilde AM","Budaj A","Morrow DA","Gause-Nilsson I","Ray KK","Mosenzon O","Leiter LA","Goodrich EL","McGuire DK","Parkhomenko A","Sabatine MS","Zelniker TA","Cahn A","Fredriksson M","Bhatt DL","Wilding J","Averkov O"],"additional_accession":[]},"is_claimable":false,"name":"Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes: A Secondary Analysis of the DECLARE-TIMI 58 Trial.","description":"<h4>Importance</h4>Dapagliflozin reduces the risk of hospitalizations for heart failure and the progression of chronic kidney disease in patients with and without type 2 diabetes (T2D), whereas the effects on reducing atherosclerotic events appear less clear.<h4>Objective</h4>To explore whether N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin T (hsTnT) levels can identify a subset of patients with T2D at higher risk and who might benefit more from dapagliflozin with regard to atherosclerotic events.<h4>Design, setting, and participants</h4>This was a secondary analysis of the DECLARE-TIMI 58 trial, a randomized clinical trial of dapagliflozin in patients with T2D and either multiple risk factors for atherosclerotic cardiovascular disease (ASCVD; a","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 May","modification":"2026-06-01T17:22:28.805Z","creation":"2025-04-04T20:40:41.24Z"},"accession":"S-EPMC9979005","cross_references":{"pubmed":["36857035"],"doi":["10.1001/jamacardio.2023.0019"]}}